Stock listing
Frankfurt:0QF Moderna, Inc. Aktie
German listing (Frankfurt) of Moderna, Inc. · home listing NASDAQ:MRNA
Follow Moderna, Inc. into a list and get an email when it puts out news.
Share price · FWB:0QF
€174.26 EUR -7.36 (-4.1%)
Close on Nov 20, 2026
- Day range
- €174.26 – €190.12 EURNov 20, 2026
- Volume
- 580 sharesNov 20, 2026
- Market cap
- €69.57B EURAt the close on Nov 20, 2026 · price × 399.2M shares outstanding
- 52-week range
- €19.17 – €237.27 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €979,210 EURMedian day 2,319 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MRNA · Home | $195.00 USD | -1.79 (-0.9%) | 9,662,576 | $200.08 | $210.00 | $191.46 | $196.79 | Close on Nov 20, 2026 |
| Xetra:0QF | €182.80 EUR | +0.44 (+0.2%) | 17,658 | €180.62 | €191.00 | €178.20 | €182.36 | Close on Nov 20, 2026 |
| B3:M1RN34 | 59.00 BRL | +1.60 (+2.8%) | 66,766 | 58.21 | 60.50 | 57.00 | 57.40 | Close on Nov 19, 2026 |
| Frankfurt:0QF | €174.26 EUR | -7.36 (-4.1%) | 580 | €179.20 | €190.12 | €174.26 | €181.62 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:0QF · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €230.61 | +16.49 | +7.7% | €217.28 | €237.27 | €208.42 | 2,344 | |
| €214.11 | -11.79 | -5.2% | €230.54 | €231.58 | €213.44 | 3,904 | |
| €225.91 | +21.92 | +10.7% | €203.57 | €226.03 | €201.55 | 3,519 | |
| €203.99 | +4.92 | +2.5% | €196.55 | €211.22 | €195.00 | 821 | |
| €199.07 | +1.325 | +0.7% | €198.59 | €200.18 | €196.63 | 970 | |
| €197.74 | -0.144 | -0.1% | €199.80 | €202.03 | €197.57 | 17,364 | |
| €197.89 | +3.767 | +1.9% | €194.86 | €199.25 | €194.15 | 373 | |
| €194.12 | +7.69 | +4.1% | €185.42 | €195.27 | €183.26 | 1,149 | |
| €186.43 | +9.064 | +5.1% | €173.56 | €188.23 | €162.75 | 5,834 | |
| €177.37 | -5.234 | -2.9% | €176.33 | €179.57 | €157.75 | 52,269 | |
| €182.60 | +1.641 | +0.9% | €178.23 | €183.23 | €170.02 | 7,892 | |
| €180.96 | -42.14 | -18.9% | €214.60 | €216.84 | €161.96 | 2,958 | |
| €223.10 | +7.318 | +3.4% | €216.24 | €224.15 | €215.33 | 1,192 | |
| €215.78 | +15.10 | +7.5% | €204.64 | €216.42 | €192.40 | 1,421 | |
| €200.68 | +8.697 | +4.5% | €195.17 | €204.10 | €191.74 | 770 | |
| €191.98 | -18.80 | -8.9% | €211.17 | €211.17 | €186.90 | 0 | |
| €210.78 | +8.794 | +4.4% | €201.02 | €216.83 | €197.31 | 1,276 | |
| €201.99 | +9.861 | +5.1% | €192.78 | €202.36 | €189.42 | 1,564 | |
| €192.13 | +2.062 | +1.1% | €189.79 | €193.66 | €182.82 | 928 | |
| €190.06 | -9.238 | -4.6% | €199.84 | €206.54 | €188.27 | 5,392 | |
| €199.30 | +23.13 | +13.1% | €176.09 | €201.25 | €174.73 | 114 | |
| €176.17 | +4.194 | +2.4% | €173.87 | €176.22 | €172.15 | 100 | |
| €171.98 | +1.912 | +1.1% | €164.90 | €172.45 | €163.43 | 338 | |
| €170.06 | -10.32 | -5.7% | €184.00 | €184.64 | €168.76 | 4,470 | |
| €180.38 | +12.57 | +7.5% | €169.02 | €181.80 | €167.20 | 3,226 | |
| €167.81 | -2.773 | -1.6% | €168.16 | €170.12 | €162.49 | 6,668 | |
| €170.58 | +0.248 | +0.1% | €168.11 | €176.32 | €163.34 | 1,986 | |
| €170.34 | -9.027 | -5.0% | €180.05 | €180.50 | €161.87 | 2,319 | |
| €179.36 | +5.082 | +2.9% | €171.32 | €183.04 | €170.57 | 1,659 | |
| €174.28 | +0.371 | +0.2% | €169.75 | €175.56 | €167.77 | 2,539 | |
| €173.91 | +4.468 | +2.6% | €174.17 | €175.63 | €170.10 | 110,482 | |
| €169.44 | +8.923 | +5.6% | €156.46 | €170.16 | €154.75 | 2,311 | |
| €160.52 | +1.609 | +1.0% | €158.63 | €165.11 | €157.73 | 4,061 | |
| €158.91 | +7.765 | +5.1% | €148.97 | €162.04 | €146.46 | 3,136 | |
| €151.14 | +19.00 | +14.4% | €135.24 | €154.60 | €135.21 | 6,819 | |
| €132.15 | -5.436 | -4.0% | €139.90 | €142.11 | €131.78 | 865 | |
| €137.58 | +10.92 | +8.6% | €128.42 | €141.80 | €128.05 | 3,140 | |
| €126.67 | +1.936 | +1.6% | €124.43 | €128.42 | €124.27 | 4,058 | |
| €124.73 | -0.76 | -0.6% | €124.84 | €125.20 | €124.68 | 1,845 | |
| €125.49 | -0.03 | 0.0% | €124.33 | €127.54 | €124.07 | 420 | |
| €125.52 | +9.527 | +8.2% | €116.58 | €128.79 | €116.36 | 4,950 | |
| €115.99 | -2.573 | -2.2% | €116.53 | €116.79 | €113.44 | 1,206 | |
| €118.57 | -3.906 | -3.2% | €120.76 | €122.29 | €117.99 | 1,047 | |
| €122.47 | -1.779 | -1.4% | €122.94 | €124.65 | €121.51 | 460 | |
| €124.25 | -0.022 | 0.0% | €125.15 | €126.24 | €124.05 | 836 | |
| €124.27 | +0.548 | +0.4% | €125.49 | €133.18 | €122.61 | 28 | |
| €123.73 | -5.806 | -4.5% | €128.39 | €129.27 | €122.50 | 2,522 | |
| €129.53 | -3.129 | -2.4% | €129.81 | €131.21 | €127.17 | 1,854 | |
| €132.66 | +10.09 | +8.2% | €119.10 | €133.77 | €118.62 | 3,182 | |
| €122.57 | +4.473 | +3.8% | €118.14 | €123.35 | €116.73 | 1,448 | |
| €118.10 | -2.999 | -2.5% | €122.05 | €125.99 | €115.59 | 3,960 | |
| €121.10 | -7.074 | -5.5% | €127.56 | €128.29 | €119.20 | 2,710 | |
| €128.17 | -6.732 | -5.0% | €136.58 | €136.87 | €125.50 | 2,343 | |
| €134.90 | +15.81 | +13.3% | €120.40 | €135.52 | €119.60 | 6,520 | |
| €119.09 | -7.097 | -5.6% | €124.76 | €125.66 | €111.77 | 6,145 | |
| €126.19 | +14.62 | +13.1% | €111.15 | €135.93 | €110.40 | 632 | |
| €111.57 | -38.86 | -25.8% | €142.41 | €143.46 | €109.55 | 22,872 |
- Ticker
- Frankfurt:0QF
- Asset type
- Stock
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Moderna Outlines Next Phase of Growth at Analyst Day
Latest earnings call · Nov 6, 2026
Moderna (NASDAQ:MRNA) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 12, 2026
Investor Day (November 2026)
Investor day · 183 slides
Latest news
Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 6, 2026
Closed €230.61 (+7.7%) on Nov 6, 2026
Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Nov 5, 2026
Closed €230.61 (+7.7%) on Nov 6, 2026
Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study
Nov 4, 2026
Closed €214.11 (-5.2%) on Nov 5, 2026
Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting
Nov 4, 2026
Closed €225.91 (+10.7%) on Nov 4, 2026
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
Oct 23, 2026
Closed €182.60 (+0.9%) on Oct 23, 2026
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Oct 22, 2026
Closed €182.60 (+0.9%) on Oct 23, 2026
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
Oct 13, 2026
Closed €192.13 (+1.1%) on Oct 13, 2026
Moderna, Inc. on 6ix
- News releases
- 58 in the last 12 months · 398 in all · newest Nov 12, 2026 · oldest 2021
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 6, 2026
- Decks
- 65 decks · latest Nov 12, 2026
Where Moderna, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MRNA · Home listing | NASDAQ | United States | USD |
| gettex:0QF | gettex | Germany | EUR |
| Milan:1MRNA | Milan | Italy | EUR |
| Xetra:0QF | Xetra | Germany | EUR |
| Tradegate:0QF | Tradegate | Germany | EUR |
| BCBA:MRNA | BCBA | Argentina | ARS |
| LS Exchange:A2N9D9 | LS Exchange | Germany | EUR |
| BMV:MRNA | BMV | Mexico | MXN |
| B3:M1RN34 | B3 | Brazil | BRL |
| BOATS:MRNA | BOATS | United States | USD |
| EUROTLX:4MRNA | EUROTLX | Italy | EUR |
| Lang & Schwarz:A2N9D9 | Lang & Schwarz | Germany | EUR |
| LSIN:0A45 | LSIN | United Kingdom | USD |
| BIVA:MRNA | BIVA | Mexico | MXN |
| BCBA:MRNAD | BCBA | Argentina | USD |
| Stuttgart:0QF | Stuttgart | Germany | EUR |
| Frankfurt:0QF · This page | Frankfurt | Germany | EUR |
| Aquis:0QFD | Aquis | United Kingdom | EUR |
| SIX Swiss:MRNA | SIX Swiss | Switzerland | CHF |
| Munich:0QF | Munich | Germany | EUR |
| VIE:MRNA | Vienna | Austria | EUR |
| SIX Swiss:MRNA.USD | SIX Swiss | Switzerland | USD |
| BCBA:MRNAC | BCBA | Argentina | USD |
| Dusseldorf:0QF | Dusseldorf | Germany | EUR |
| BX Swiss:0QF | BX Swiss | Switzerland | CHF |
| Hamburg:0QF | Hamburg | Germany | EUR |
| BSESOF:0QF | BSESOF | Bulgaria | EUR |
| BVL:MRNAUS | BVL | Peru | PEN |
| Hanover:0QF | Hanover | Germany | EUR |
| Turquoise:MRNAN | Turquoise | United Kingdom | USD |
| Aquis:0QFD | Aquis | United Kingdom | EUR |
| BCBA:MRNA.CI | BCBA | Argentina | ARS |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $77.91B USD
- P/E
- Loss
- EV/sales
- 30.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 11.5×
- Gross margin
- 28.0%
- Operating margin
- −116.0%
- Net margin
- −110.5%
- Debt to equity
- 0.6×
- Beta vs S&P 500
- 1.96
Forecasts
3 strong buy · 1 buy · 16 hold · 1 sell · 2 strong sell · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 155.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -7.40 · 18 analysts
- Revenue, year to Dec 2026
- 2.42B · 16 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Stéphane Bancel | Chief Executive Officer, Moderna |
| Lavina Talukdar | Senior Vice President & Head of Investor Relations |
| Chris Ridley | VP, Global Head of Communications |
| Noubar Afeyan | Co-founder, Chairman, Moderna, Flagship Pioneering |
| Tracey Franklin | Chief People Officer |
Board
| Director | Role |
|---|---|
| Noubar Afeyan | Co-founder, Chairman, Moderna, Flagship Pioneering |
| Michael McDonnell | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Moderna (NASDAQ:MRNA) Q3 2026 Earnings Call | Fri, Nov 06, 2026 · 8:00 AM ET | Replay |
| Moderna (NASDAQ:MRNA) Q2 2026 Earnings Call | Fri, Jul 31, 2026 · 8:00 AM ET | Replay |
| Moderna (NASDAQ:MRNA) Q1 2026 Earnings Call | Fri, May 01, 2026 · 8:00 AM ET | Replay |
| Moderna (NASDAQ:MRNA) Q4 2025 Earnings Call | Fri, Feb 13, 2026 · 8:00 AM ET | Replay |
| Moderna (NASDAQ:MRNA) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:00 AM ET | Replay |
| Moderna (NASDAQ:MRNA) Q2 2025 Earnings Call | Fri, Aug 01, 2025 · 8:00 AM ET | Replay |
| Moderna (NASDAQ:MRNA) Q1 2025 Earnings Call | Thu, May 01, 2025 · 8:00 AM ET | Replay |
| Moderna (NASDAQ:MRNA) Q4 2024 Earnings Call | Fri, Feb 14, 2025 · 8:00 AM ET | Replay |
| Moderna (NASDAQ:MRNA) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 8:00 AM ET | Replay |
| Moderna (NASDAQ:MRNA) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 8:00 AM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 6, 2026 · Before open | +5.3% |
| Q2 2026 | Jul 31, 2026 · Before open | −5.3% |
| Q1 2026 | May 1, 2026 · Before open | −1.2% |
| Q4 2025 | Feb 13, 2026 · Before open | +5.3% |
| Q3 2025 | Nov 6, 2025 · Before open | +3.3% |
| Q2 2025 | Aug 1, 2025 · Before open | −6.6% |
| Q1 2025 | May 1, 2025 · Before open | −5.3% |
| Q4 2024 | Feb 14, 2025 · Before open | +3.4% |
| Q3 2024 | Nov 7, 2024 · Before open | −3.0% |
| Q2 2024 | Aug 1, 2024 · Before open | −21.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · Before open | +12.7% |
| Q4 2023 | Feb 22, 2024 · Before open | +13.5% |
| Q3 2023 | Nov 2, 2023 · Before open | −6.5% |
| Q2 2023 | Aug 3, 2023 · Before open | −0.2% |
| Q1 2023 | May 4, 2023 · Before open | +3.2% |
| Q4 2022 | Feb 23, 2023 · Before open | −6.7% |
| Q3 2022 | Nov 3, 2022 · Before open | −0.8% |
| Q2 2022 | Aug 3, 2022 · Before open | +16.0% |
| Q1 2022 | May 4, 2022 · Before open | +5.8% |
| Q4 2021 | Feb 24, 2022 · Before open | +15.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (November 2026) | Investor day | 183 slides | Nov 12, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Nov 6, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 29 slides | Jul 31, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 25 slides | May 1, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 26 slides | Feb 13, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference 2026 | Conference | 24 slides | Jan 12, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 26 slides | Nov 6, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 31 slides | Aug 1, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 29 slides | May 1, 2025 |
| 35th Congress of the European Society of Clinical Microbiology & Infectious Diseases (ESCM (April 2025) | Conference | 14 slides | Apr 12, 2025 |
Show 50 decks
This page holds 50 of 65 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| 0.00% Convertible Senior Notes due 2032 Made bigger: US$2.6B Use of proceeds: Pay about $285.0 million for capped call transactions and general corporate purposes, possibly including growing the oncology business and repaying debt | Aug 28, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.94B | 3.24B | 6.85B | 19.3B | 18.5B | 803.0M | 60.0M | 135.1M | 205.8M | 108.4M |
| Cost of revenue | 868.0M | 1.46B | 4.69B | 5.42B | 2.62B | 8.00M | 0 | 0 | 20.5M | 15.1M |
| Gross profit | 1.08B | 1.74B | 2.15B | 13.5B | 15.1B | 266.6M | 48.0M | -331.6M | 185.3M | 93.3M |
| Research and development | 3.13B | 4.54B | 4.84B | 3.29B | 1.99B | 1.37B | 496.0M | 454.1M | 410.5M | 274.7M |
| Selling, general and administrative | 1.02B | 1.03B | 1.34B | 1.01B | 567.0M | 188.3M | 109.6M | 94.3M | 64.7M | 57.5M |
| Operating income | -3.07B | -3.94B | -4.24B | 9.42B | 13.3B | -763.0M | -546.0M | -413.3M | -269.4M | -223.8M |
| Depreciation and amortization | 211.0M | 185.0M | 617.0M | 348.0M | 232.0M | 31.0M | 31.0M | 24.9M | 20.5M | 15.1M |
| EBITDA | -2.86B | -3.76B | -3.62B | 9.77B | 13.5B | -732.0M | -515.0M | -388.4M | -248.8M | -208.7M |
| Interest expense | 10.0M | 24.0M | 38.0M | 29.0M | 18.0M | 9.89M | 6.61M | 3.10M | 132.0K | 0 |
| Income before tax | -2.77B | -3.61B | -3.94B | 9.57B | 13.3B | -744.0M | -515.0M | -384.4M | -256.0M | -215.2M |
| Income tax | 54.0M | -46.0M | 772.0M | 1.21B | 1.08B | 3.00M | -1.00M | 326.0K | -80.0K | 1.04M |
| Net income | -2.82B | -3.56B | -4.71B | 8.36B | 12.2B | -747.0M | -514.0M | -384.7M | -255.9M | -216.2M |
| Earnings per share, basic | -7.26 | -9.28 | -12.33 | 21.26 | 30.31 | -1.96 | -1.55 | -4.95 | -4.18 | -3.79 |
| Earnings per share, diluted | -7.26 | -9.28 | -12.33 | 20.12 | 28.29 | -1.96 | -1.55 | -4.95 | -4.18 | -3.79 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.60B | 1.93B | 2.91B | 3.21B | 6.85B | 2.62B | 236.0M | 658.4M | 134.9M | 50.1M |
| Short-term investments | 3.20B | 5.10B | 5.70B | 6.70B | 3.88B | 1.98B | 867.1M | 863.1M | 621.2M | 1.01B |
| Receivables | 184.0M | 358.0M | 892.0M | 1.39B | 3.17B | 1.39B | 5.37M | 11.7M | 11.9M | 18.0M |
| Inventory | 153.0M | 117.0M | 202.0M | 949.0M | 1.44B | 47.0M | 0 | -173.0M | ||
| Current assets | 6.54B | 8.10B | 10.3B | 13.4B | 16.1B | 6.30B | 1.13B | 1.56B | 783.2M | 1.09B |
| Property, plant and equipment | 2.14B | 1.38B | 387.1M | 287.9M | 212.0M | 139.0M | 81.2M | |||
| Goodwill | 52.0M | 52.0M | 52.0M | 0 | 3.50M | 3.56M | ||||
| Total assets | 12.3B | 14.1B | 18.4B | 25.9B | 24.7B | 7.34B | 1.59B | 1.96B | 1.08B | 1.42B |
| Accounts payable | 317.0M | 405.0M | 520.0M | 487.0M | 302.0M | 18.0M | 7.09M | 31.2M | 20.7M | 28.2M |
| Current liabilities | 1.99B | 2.21B | 3.02B | 4.92B | 9.13B | 4.39B | 143.1M | 222.8M | 191.5M | 162.8M |
| Long-term debt | 590.0M | 0 | 15.7M | 12.5M | ||||||
| Total debt | 590.0M | 0 | 1.24B | 1.20B | 916.0M | 237.0M | 132.4M | 112.6M | 88.4M | 37.6M |
| Total liabilities | 3.69B | 3.24B | 4.57B | 6.74B | 10.5B | 4.78B | 414.6M | 431.9M | 459.2M | 575.3M |
| Shareholders' equity | 8.65B | 10.9B | 13.9B | 19.1B | 14.1B | 2.56B | 1.18B | 1.53B | -551.4M | -334.8M |
| Shares outstanding | 394.0M | 386.0M | 382.0M | 385.0M | 403.0M | 399.0M | 336.5M | 328.8M | 65.2M | 368.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.87B | -3.00B | -3.12B | 4.98B | 13.6B | 2.03B | -459.0M | -330.9M | -331.5M | 66.7M |
| Capital spending | -192.0M | -1.05B | -707.0M | -400.0M | -284.0M | -68.0M | -32.0M | -105.8M | -58.4M | -33.1M |
| Free cash flow | -2.06B | -4.05B | -3.83B | 4.58B | 13.3B | 1.96B | -491.0M | -436.6M | -389.9M | 33.6M |
| Cash from investing | 1.95B | 1.95B | 4.21B | -5.18B | -8.52B | -1.67B | -15.0M | -373.1M | 417.4M | -648.6M |
| Cash from financing | 593.0M | 56.0M | -1.38B | -3.45B | -873.0M | 2.03B | 52.0M | 1.23B | 168.0K | 472.9M |
| Dividends paid | -270.0M | -184.0M | -124.0M | -7.04M | -1.48M | -633.0K | ||||
| Share buybacks | -2.00M | 0 | -1.15B | -3.33B | -857.0M | 0 | 0 | -8.18M | 0 | 0 |
| Change in cash | 668.0M | -999.0M | -289.0M | -3.64B | 4.22B | 2.39B | -422.0M | 522.9M | 86.0M | -109.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 16, 2026 | Material contract | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 13, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Nov 9, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 1, 2026 | Material contract | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 5, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 31, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| 8-K · Current report | May 11, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 1, 2026 | Quarterly report | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 8-K · Current report | May 1, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Mar 16, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 16, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 16, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 20, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 20, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 13, 2026 | Results | SEC |
| 8-K · Current report | Feb 10, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2026 | Current report | SEC |
| SC TO-I/A | Dec 16, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 24, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 20, 2025 | Current report | SEC |
| SC TO-I/A | Nov 18, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Nov 13, 2025 | Meeting outcome | SEC |
| SC TO-I | Nov 13, 2025 | Acquisition or disposal | SEC |
| SC TO-C | Nov 12, 2025 | Other filings | SEC |
| SC TO-C | Nov 6, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| SC TO-C | Oct 21, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Oct 20, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 15, 2025 | Meeting notice | SEC |
| SC TO-C | Oct 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| SC TO-C | Oct 3, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Oct 3, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 6, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 5, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Mar 11, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 11, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 11, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 21, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 21, 2025 | Annual report | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
This page holds 200 of 1,003 filings. Open Filings
Cap table
Built by 6ix from Moderna, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 404,620,975
- Fully diluted
- 404,620,975
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 404,620,975 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 404,620,975 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Noubar Afeyan Other companies: Generate Biomedicines, Inc. (Chair of the Board · Since at least Feb 26, 2026); Foghorn Therapeutics Inc. (Director · Since at least Jan 13, 2026); BG Medicine Inc (Director · Since at least Feb 3, 2011); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Mar 4, 2019 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 21, 2016 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past); Agenus Inc. (Director · Jan 13, 2005 – Jun 7, 2007 · Past) | Director · Since at least Dec 7, 2018 |
| François Nader Other companies: Tectonic Therapeutic, Inc. (Chair, Board of Directors · Since at least Feb 23, 2026); Tourmaline Bio Inc. (Director · May 6, 2021 – Jun 13, 2023 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Alexion Pharmaceuticals Inc (Director · Nov 15, 2017 – Jul 21, 2021 · Past); Baxalta Inc (Director · Jul 27, 2015 – Jun 3, 2016 · Past); Acceleron Pharma Inc (Director · Dec 11, 2014 – Nov 19, 2021 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 20, 2015 · Past); NPS Pharmaceuticals Inc (President, CEO and Director, Director · Apr 8, 2013 – Feb 21, 2015 · Past) | Director · Since at least Dec 10, 2019 |
| Paul Sagan Other companies: Okta, Inc. (Director · Since at least Dec 19, 2025); Catalyst Partners Acquisition Corp (President, Director · May 17, 2021 – Feb 7, 2023 · Past); VMware Inc (Director · Apr 7, 2014 – Nov 22, 2023 · Past); iRobot Corporation (Director · Feb 1, 2010 – Jun 5, 2015 · Past); EMC Corporation (Director · Dec 19, 2007 – Sep 6, 2016 · Past); Dow Jones & Co Inc (Director · Apr 18, 2007 – Dec 13, 2007 · Past); Digitas Inc (Director · Jul 25, 2006 – Jan 25, 2007 · Past); Akamai Technologies, Inc. (Director · Oct 4, 2005 – May 15, 2019 · Past) | Director · Dec 7, 2018 – Apr 30, 2025 · Past |
| David Meline Other companies: Lonza Group AG (Independent Member of the Board of Directors · Since at least May 8, 2026); Eikon Therapeutics, Inc. (Director · Since at least Feb 4, 2026); HP Inc. (Director · Since at least Nov 1, 2023); Pacific Biosciences of California, Inc. (Director · Oct 13, 2023 – Jun 18, 2024 · Past); Amgen Inc. (EVP & CFO · Jul 21, 2014 – Nov 25, 2019 · Past); TRW Automotive Holdings Corp (Director · Feb 12, 2014 – May 13, 2014 · Past); 3M Company (Former Sr. VP & CFO · Sep 2, 2008 – Apr 30, 2014 · Past) | Chief Financial Officer · Jun 8, 2020 – Aug 9, 2022 · Past |
| Robert Langer Other companies: Seer, Inc. (Director · Since at least Dec 3, 2020); Lyra Therapeutics, Inc. (David H. Koch Institute Professor, Massachusetts Institute of Technology · Since at least Apr 30, 2020); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – Oct 14, 2019 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 12, 2018 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Jun 21, 2016 · Past); Ocata Therapeutics Inc (Director · Oct 4, 2011 – Feb 10, 2016 · Past) | Director · Dec 7, 2018 – May 6, 2024 · Past |
| Michael McDonnell Other companies: Baxter International Inc. (Director · Since at least Feb 13, 2026); Merit Medical Systems, Inc. (Audit Committee · Since at least May 19, 2022); Biogen Inc. (EVP, Chief Financial Officer · Aug 15, 2020 – Feb 10, 2025 · Past); Frontier Communications Corporation (Director · Dec 12, 2018 – Apr 1, 2019 · Past); IQVIA Holdings, Inc. (EVP and CFO · Dec 16, 2015 – Jul 5, 2020 · Past) | Director · Since at least Jul 8, 2026 |
| Sandra J. Horning Other companies: Revolution Medicines, Inc. (Director · Since at least Nov 9, 2023); Olema Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2020); Gilead Sciences, Inc. (Director · Since at least Jan 28, 2020); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Foundation Medicine Inc (Director · Apr 7, 2015 – Apr 7, 2015 · Past) | Director · Since at least Apr 29, 2020 |
| John Mendlein Other companies: Fate Therapeutics, Inc. (Director · Since at least Sep 30, 2013); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 20, 2024 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Jun 15, 2017 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 8, 2019 · Past) | See Remarks · Dec 7, 2018 – Dec 7, 2018 · Past |
| Jorge M Gomez Other companies: Pear Therapeutics Inc (Director · Dec 3, 2021 – Dec 3, 2021 · Past); Dentsply Sirona Inc. (EVP, CFO · Aug 26, 2019 – Apr 8, 2022 · Past); Xylem Inc. (Director · Mar 27, 2019 – May 11, 2022 · Past); Cardinal Health, Inc. (Chief Financial Officer · Jan 1, 2018 – Nov 8, 2018 · Past) | See Remarks · May 9, 2022 – May 9, 2022 · Past |
| Lorence H Kim Other companies: Cencora, Inc. (Director · Since at least Oct 1, 2022); Revolution Medicines, Inc. (Director · Since at least Jul 12, 2022); Cowen Group Inc (Director · Feb 15, 2022 – Mar 1, 2023 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 13, 2019 · Past) | Chief Financial Officer · Dec 7, 2018 – Jun 2, 2020 · Past |
All 32 people
| Person | Seat |
|---|---|
| Stéphane Bancel Other companies: Generate Biomedicines, Inc. (Director · Since at least Feb 26, 2026); BG Medicine Inc (Executive Chairman of the Board · Since at least Feb 3, 2011); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Sep 15, 2016 · Past); Targanta Therapeutics Corp (Director · Aug 25, 2008 – Aug 25, 2008 · Past) | Chief Executive Officer, Moderna · Since at least Dec 7, 2018 |
| Corinne Le Goff Other companies: Viatris Inc. (Chief Commercial Officer · Since at least Apr 15, 2024); Imunon, Inc. (President and CEO, Director · Jul 18, 2022 – Mar 17, 2023 · Past); Longboard Pharmaceuticals Inc (Director · Mar 11, 2021 – Dec 2, 2024 · Past) | Chief Commercial Officer · Jan 19, 2021 – Feb 1, 2021 · Past |
| Elizabeth E Tallett Other companies: Elevance Health, Inc. (Director · May 19, 2016 – May 15, 2024 · Past); Meredith Corporation (Director · Nov 11, 2015 – Nov 9, 2021 · Past); Principal Financial Group Inc (Director · Aug 14, 2015 – Jun 25, 2021 · Past) | Director · Since at least Jul 1, 2020 |
| Elizabeth Nabel Other companies: Lyell Immunopharma, Inc. (Director · Since at least Jun 16, 2021); Medtronic plc. (Director · Since at least Sep 16, 2014); Accolade, Inc. (Director · Jun 2, 2021 – Apr 8, 2025 · Past) | Director · Since at least Dec 7, 2018 |
| Juan Andres Other companies: Lonza Group AG (Independent Member of the Board of Directors · Since at least May 8, 2026); Evelo Biosciences, Inc. (Director · Dec 4, 2019 – Jun 8, 2023 · Past); Avantor, Inc. (Director · Sep 20, 2019 – May 8, 2025 · Past) | See remarks · Dec 7, 2018 – Dec 28, 2022 · Past |
| Moncef Slaoui Other companies: Arcturus Therapeutics Holdings Inc. (Director · Since at least Jun 19, 2024); Vaxcyte, Inc. (Director · Since at least Jun 11, 2020); Intellia Therapeutics, Inc. (Director · Jul 24, 2017 – Jul 25, 2017 · Past) | Director · Dec 7, 2018 – Apr 29, 2020 · Past |
| Tal Zaks Other companies: Teva Pharmaceutical Industries Limited (Independent Director · Since at least Oct 1, 2021); Adaptimmune Therapeutics PLC (Director · Nov 14, 2016 – Jul 1, 2022 · Past) | Chief Medical Officer · Dec 7, 2018 – Jun 30, 2021 · Past |
| Abbas Hussain Other companies: Mallinckrodt Inc (Director · Since at least Feb 2, 2024) | Director · Since at least Oct 2, 2024 |
| David M. Rubenstein Other companies: The Carlyle Group Inc. (Partner, Co-Founder and Co-Chairman · Since at least May 3, 2012) | Director · Since at least Aug 5, 2024 |
| Israel Ruiz Other companies: Fortive Corporation (Director · Jun 13, 2016 – Jun 4, 2019 · Past) | Director · Dec 7, 2018 – Jun 27, 2019 · Past |
| Jennifer Ling Lee Other companies: Standard BioTools Inc. (See Remarks · May 18, 2016 – Feb 20, 2018 · Past) | Chief Accounting Officer · Dec 7, 2018 – Mar 9, 2020 · Past |
| Lori M Henderson Other companies: Albany Molecular Research Inc (SVP, Secretary & Gen Counsel · Nov 2, 2016 – Aug 31, 2017 · Past) | General Counsel and Secretary · Dec 7, 2018 – May 27, 2021 · Past |
| Paul Burton Other companies: Amgen Inc. (Senior Vice President and Chief Medical Officer · Since at least Oct 27, 2026) | Chief Medical Officer · Jul 5, 2021 – Nov 4, 2022 · Past |
| Shannon Thyme Klinger Other companies: Rafael Holdings, Inc. (Director · Jun 14, 2021 – Jan 5, 2022 · Past) | Chief Legal Officer · Since at least Jun 1, 2021 |
| Soria Ester Banque Other companies: Zoetis Inc. (Executive Vice President · Jul 10, 2023 – Oct 4, 2024 · Past) | Chief Commercial Officer · Since at least Jun 15, 2026 |
| Stephen Berenson Other companies: Seres Therapeutics, Inc. (Director · Since at least Jun 22, 2022) | Director · Apr 28, 2022 – May 3, 2024 · Past |
| Stephen Hoge Other companies: Axcella Health Inc (Director · May 8, 2019 – May 20, 2021 · Past) | President · Since at least Dec 7, 2018 |
| Arpa Garay | Chief Commercial Officer · Dec 5, 2023 – Dec 5, 2023 · Past |
| Chris Ridley | VP, Global Head of Communications · Since at least Oct 23, 2026 |
| James M Mock | Chief Financial Officer · Since at least Apr 4, 2025 |
| Lavina Talukdar | Senior Vice President & Head of Investor Relations · Since at least Oct 23, 2026 |
| Tracey Franklin | Chief People Officer · Since at least Oct 23, 2026 |
Log in to ask 6ix AI your own questions about Moderna, Inc.